Dr. Sulaiman Al Habib Medical Services Group (4013) Fundamentals 2026 — P/E 31.6x, Revenue Analysis | SniperIQ
Dr. Sulaiman Al Habib Medical Services Group (4013) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 74.3B, trading at SAR 212.30 on the SAU. This SniperIQ fundamentals page covers Dr. Sulaiman Al Habib Medical Services Group's valuation (P/E 31.6x, P/B 9.3x), profitability (net margin 16.8%), revenue (SAR 13.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dr. Sulaiman Al Habib Medical Services Group's market cap?
Dr. Sulaiman Al Habib Medical Services Group (4013) has a market capitalization of approximately SAR 74.3B, trading at SAR 212.30 on the SAU. Market cap moves with the live share price.
What is Dr. Sulaiman Al Habib Medical Services Group's P/E ratio?
Dr. Sulaiman Al Habib Medical Services Group's trailing twelve-month P/E ratio is 31.6x, with a price-to-book (P/B) of 9.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dr. Sulaiman Al Habib Medical Services Group?
Dr. Sulaiman Al Habib Medical Services Group runs a net profit margin of 16.8%, a gross margin of 29.6%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dr. Sulaiman Al Habib Medical Services Group generate?
Dr. Sulaiman Al Habib Medical Services Group reported revenue of SAR 13.7B for fiscal year 2025, with net income of SAR 2.4B and earnings per share (EPS) of 6.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dr. Sulaiman Al Habib Medical Services Group pay a dividend?
Dr. Sulaiman Al Habib Medical Services Group offers a trailing dividend yield of about 2.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dr. Sulaiman Al Habib Medical Services Group financially healthy?
Dr. Sulaiman Al Habib Medical Services Group carries a debt-to-equity ratio of 1.20x and a current ratio of 1.14x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dr. Sulaiman Al Habib Medical Services Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dr. Sulaiman Al Habib Medical Services Group (4013) the key facts are: market cap SAR 74.3B, P/E 31.6x, revenue SAR 13.7B, 52-week range 210.1-281.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dr. Sulaiman Al Habib Medical Services Group's full fundamentals live
Get Dr. Sulaiman Al Habib Medical Services Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.